Many of the compounds that are used in clinical medicine for treatment of infectious diseases interfere with protein synthesis by targeting the ribosome 1 , e.g., macrolides, ketolides, lincosamides, oxazolidinones, aminoglycosides, and tetracyclines. In general, antibiotics target the ribosome at locations of functional relevance, e.g., decoding, translocation, and peptidyl transfer. The increasing incidence of antibiotic resistance and the toxicity associated with some of the available agents constitute a formidable challenge for further exploitation of the ribosome as a drug target. The principle of antimicrobial chemotherapy dates back to Paul Ehrlichs concept of selective toxicity. The ribosome is a highly conserved structure present in all three kingdoms of life: archea, bacteria, and eukaryotes. How can ribosomal inhibitors fulfil the principle of selective toxicity? Drugs targeting the ribosome are characterized by two features: specificity (see Table 1 ) and toxicity. Ribosomal inhibitors, which are used in clinical medicine for treatment of infectious diseases, exhibit varying degrees of toxicity. Macrolides and lincosamides show very little toxicity, if any, while the therapeutic use of aminoglycosides is limited by significant ototoxicity and nephrotoxicity. How to explain these different degrees of toxicity? What is the basis for drug selectivity? The ribosome is a complex macromolecular structure which consists of a large and a small subunit. These two subunits are composed of dozens of different proteins, and nucleic acids, termed rRNA. During the past decades, considerable evidence has accumulated demonstrating that the nucleic acid component of the ribosome is key to binding many of the ribosomal drugs, rather than the numerous ribosomal proteins 1 -3 . Recent data from X-ray crystallography have not only confirmed this suggestion but also provided details of drug-target interactions at the atomic level by revealing how antibiotic binding occurs 4 -8 . The eukaryotic ribosome comes in two flavors: the cytoplasmic and the mitochondrial ribosome. The components of the cytoribosome are encoded by chromosomal genes as are the mitoribosomal proteins. However, the rRNA components of the mitoribosome are encoded by the mitochondrial genome (www.mitomap.org). Although the basis for drugrelated toxicity of the ribosomal inhibitors is unknown, several lines of evidence point to mitoribosomes as the Achilles heel of ribosomal antibiotics, because: (i) mitochondrial ribosomes are more related to the prokaryotic ribosome than to the eukaryotic cytoplasmic ribosome; (ii) toxicity in vivo correlates with activity in vitro, i.e., those antibiotics which exhibit in vitro activity on mitoribosomes are associated with toxicity in vivo; (iii) familial hypersensitivity to aminoglycosides (drug-induced deafness) is associated with specific mutations in mitochondrial rRNA 9 . Investigations on and genetic manipulations of ribo-somal nucleic acids are problematic, because most eubacteria harbor multiple rRNA operons in their chromosome. For many of the antibiotics targeting the ribosome, susceptibility is dominant over resistance 10 . Thus, a merodiploid strain with a mutant resistant allele and a wild-type susceptible allele usually exhibits a drug-susceptible phenotype. As the majority of eubacteria are characterized by the presence of multiple rRNA (rrn) operons, resistanceconferring alterations in rrn were initially rarely described in clinical pathogens. In the mid 1990s mutations in rRNAs were first recognized as a significant cause of acquired drug resistance in major clinical pathogens 11 -18 . Subsequently, genetic procedures were developed which permitted the construction of eubacteria carrying a single functional rRNA operon 15, 19 . These single rRNA allelic microorganisms allow mutagenesis of their ribosomal nucleic acids to result in cells containing homogeneous populations of mutant ribosomes. Genetic, biochemical, and structural studies have provided a detailed picture of the importance of specific nucleotides for high-affinity binding of ribosomal drugs to their respective rRNA target site. Clinically useful ribosomal antibiotics must discriminate between bacterial and eukaryotic ribosomes. The high cross-species conservation of functional sites within the ribosomal RNA, targeted by ribosomal drugs, implies limitations with respect to selectivity. In the case of aminoglycosides, bacterial and mitochondrial ribosomes are susceptible, while eukaryotic cytoplasmic ribosomes are insensitive to these drugs. In contrast, while bacterial ribosomes are susceptible to macrolide antibiotics, both the mitochondrial and the eukaryotic cytoplasmic ribosome are naturally resistant to these agents 20 . It has been suggested that the analysis of drug resistance mutations in bacteria allows one to understand the basis of specificity for drugs targeting the ribosome 21 . Central to this hypothesis is the concept of informative sequence positions À i.e., the identification of polymorphic nucleotides as a determinant of ribosomal resistance. The identification of a polymorphic residue as determinant of ribosomal resistance provides information about the selectivity of a ribosomal antibiotic, i.e., why a drug affects the prokaryotic as opposed to the eukaryotic ribosome (see Table 2 ). The basis for this hypothesis was initially established by investigating bacterial alterations within the ribosome mediating resistance to aminoglycosides and macrolides. The conclusion from these studies was that the selectivity of these agents is largely due to a single nucleotide position within the rRNA, e.g., the identity of the base at 16S rRNA position 1408 determines selectivity of aminoglycosides, while the identity of the base at 23S rRNA position 2058 determines the selectivity of macrolides 21 . For aminoglycosides, selectivity is due to the natural insensitivity of eukaryotic cytoplasmic ribosomes conferred by a guanine at 16S rRNA position 1408; the toxicity of aminoglycosides (at least irreversible ototoxicity) is due to the natural susceptibility of mitoribosomes, which carry a susceptible bacterial adenine at this sequence position. Macrolides are characterized by the virtual absence of target-related toxicity; both cytoribosomes and mitoribosomes are naturally resistant to these drugs, with resistance conferred by a guanine at 23S rRNA position 2058 (Table 2) . In an effort to challenge this concept, a single rRNA allelic eubacterium was saturated with drug-resistance-conferring mutations by selecting for spontaneous resistance to hygromycin B, a universal inhibitor of translation. If a polymorphic rRNA residue had been found to confer resistance, this would have effectively falsified the concept. All of the resistance mutations were found to map to the hygromycinbinding site within helix 44 of 16S rRNA. Significantly, analysis of drug-resistance-conferring rRNA mutations revealed that these were restricted to universally conserved nucleotides 28] (Table 2, Fig. 1 ). The observation that ribosomal alterations mediating resistance by hygromycin B exclusively involve universally conserved nucleotides within rRNA explains the lack of specificity and general toxicity of hygromycin B. Linezolid is a representative of a new class of antibiotics, the oxazolidinones. These drugs inhibit protein synthesis, both in vivo and in vitro, and have activity against a wide range of Gram-positive and Gram-negative bacteria 30 . Linezolid binds to the large ribosomal subunit, and its binding site on the 23S rRNA overlaps with that of the peptidyl transferase inhibitor chloramphenicol 31 . Early on, linezolid In an effort to characterize the selectivity of the drug, we analyzed the described bacterial resistance mutations for genetic polymorphism, i.e. nucleotide positions mediating resistance which differ between the bacterial and the mitochondrial rRNA. Most of the resistance mediating nucleotide alterations were found to correspond to universally conserved positions, e.g., A2062, G2447, A2451, C2452, U2500, and G2505. However, rare positions 
Alteration of 1491G to A does not confer resistance [26, 27] . In general, the main problem in contemporary drug development is not activity, but toxicity. As far as the ribosome as drug target is concerned, the tools are available to characterize rapidly the selectivity of a compound for the bacterial versus eukaryotic (cytoplasmic, mitochondrial) ribosomes. The identification of a polymorphic rRNA residue as a resistancemediating residue nearly excludes target-related toxicity. Together with identification of functionally relevant sites in the ribosome 44 , X-ray crystallography 4 -8 , and powerful chemistry, genetics is back at the core of drug development.
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